



**Product:** BIIB037

**Protocol Number:** 221AD205

**EudraCT Number:** 2018-002102-31

**Protocol Title:** A Phase 2, Multicenter, Randomized, Parallel-Group, Double-Blind, Controlled Study of Aducanumab (BIIB037) in Subjects With Mild Cognitive Impairment due to Alzheimer's Disease or With Mild Alzheimer's Disease Dementia to Evaluate the Safety of Continued Dosing in Subjects with Asymptomatic Amyloid-Related Imaging Abnormalities

**Sponsor:** Biogen Idec Research Limited

**Subject:** Justification for no results posted on the EudraCT

---

The clinical trial was discontinued 21 Mar 2019, prior to any subject enrolment in EU. This memorandum is to document that for this reason no results-related information will be posted on the EudraCT.

A handwritten signature in black ink, appearing to read "T. Morgan Hadley", is written over a horizontal line.

T. Morgan Hadley  
Clinical Trial Transparency  
Biogen

A handwritten signature in black ink, appearing to read "T. Morgan Hadley", is written over a horizontal line.

16 Dec 2020  
Date (DD MMM YYYY)